Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410565 | 0.89 | PIM1 (0.66) | PIM1CLK1DYRK1ADYRK1BPIM2 | |
| SCHEMBL6480036 | 0.86 | FLT3 (0.47) | PIM1FLT3TP53NPC1RAB9A | |
| SCHEMBL17182493 | 0.84 | ALDH1A1 (0.56) | PIM1CLK1DYRK1ADYRK1BFLT3 | |
| Isophthalic Acid SCHEMBL27887534 | 0.80 | NPC1 (0.64) | FLT3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28322521 | 0.80 | PIM1 (0.46) | PIM1CLK1DYRK1ADYRK1BPIM2 | |
| SCHEMBL8713204 | 0.79 | TPSAB1 (0.62) | PIM1PIM2TPSAB1TPSD1TPSG1 | |
| SCHEMBL29431747 | 0.78 | FLT3 (0.76) | PIM1CLK1DYRK1ADYRK1BFLT3 | |
| SCHEMBL10508628 | 0.78 | FLT3 (0.76) | PIM1CLK1DYRK1ADYRK1BFLT3 | |
| SCHEMBL6021894 | 0.78 | FLT3 (0.76) | PIM1CLK1DYRK1ADYRK1BPIM2 | |
| SCHEMBL21211394 | 0.78 | CLK1 (0.57) | PIM1CLK1DYRK1ADYRK1BPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894042-B2 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1476448-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| WO-2003070731-A2 | AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | PIM1 3689/4885CLK1 4842/4885DYRK1A 4120/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | PIM1 3689/4885CLK1 4842/4885DYRK1A 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.